Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804–2811. https://doi.org/10.1182/blood-2014-02-522128

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R (2016) Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol 91:366–370. https://doi.org/10.1002/ajh.24278

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333:1253–1258. https://doi.org/10.1056/NEJM199511093331904

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Schrezenmeier H, Röth A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, Wilson A, Shayan G, Maciejewski JP (2020) Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. https://doi.org/10.1007/s00277-020-04052-z

  5. 5.

    Babushok DV, Stanley N, Xie HM, Huang H, Bagg A, Olson TS, Bessler M (2017) Clonal replacement underlies spontaneous remission in paroxysmal nocturnal haemoglobinuria. Br J Haematol 176:487–490. https://doi.org/10.1111/bjh.13963

    Article  PubMed  Google Scholar 

  6. 6.

    Korkama E-S, Armstrong A-E, Jarva H, Meri S (2018) Spontaneous remission in paroxysmal nocturnal hemoglobinuria—return to health or transition into malignancy? Front Immunol 9. https://doi.org/10.3389/fimmu.2018.01749

  7. 7.

    Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D (2010) ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 151:365–375. https://doi.org/10.1111/j.1365-2141.2010.08381.x

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Chloé Friedrich.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patients included in the study.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Friedrich, C., Gay, J., Alary, A. et al. Battle of the clones: paroxysmal nocturnal hemoglobinuria vs myelodysplastic syndrome. Ann Hematol (2020). https://doi.org/10.1007/s00277-020-04134-y

Download citation

Keywords

  • Paroxysmal nocturnal hemoglobinuria
  • Myelodysplastic syndrome
  • Clonal dynamics
  • ASXL1